Relative Lack of Conditional Survival Improvement in Young Adults With Cancer

Archie Bleyer, Mehee Choi, C. David Fuller, Charles Thomas, Samuel Wang

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Cancer prognosis is usually reported in terms of survival from time of diagnosis. For patients surviving a period of time after diagnosis, conditional survival (CS) accounts for changing risk over time. This report provides information on how CS in cancer patients changes as a function of age at diagnosis. Using data from the US Surveillance, Epidemiology and End Results database, we examined survival for patients diagnosed between 1973 and 2002. The average annual percent change (AAPC) in CS during the first 5 years after diagnosis was evaluated for the 14 most common cancers occurring in young adults, defined as 15- to 39-year-olds, and how they compared with cancers that are more common in older and younger patients. For all cancers, young adult patients had less CS improvement over time than younger or older patients, and this difference was most pronounced in those aged 20 to 29 years (45% below the mean). Eleven of the 14 most common cancers in 15- to 39-year-olds either had a lower CS improvement after diagnosis than either younger or older patients, or than just the older patients. Young adults with leukemia had the greatest improvement in CS over time. In conclusion, young adults with cancer have not enjoyed the same improvement in CS over time compared with other age groups. Explanations for this deficit include the biologic nature of the type of cancers in young adults and less effective therapies for patients in the age group. Regardless of the reasons, the deficit is yet another challenge faced by young adult patients that merits further study.

Original languageEnglish (US)
Pages (from-to)460-467
Number of pages8
JournalSeminars in Oncology
Volume36
Issue number5
DOIs
StatePublished - Oct 2009

Fingerprint

Young Adult
Survival
Neoplasms
Age Groups
Leukemia
Epidemiology
Databases

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Relative Lack of Conditional Survival Improvement in Young Adults With Cancer. / Bleyer, Archie; Choi, Mehee; Fuller, C. David; Thomas, Charles; Wang, Samuel.

In: Seminars in Oncology, Vol. 36, No. 5, 10.2009, p. 460-467.

Research output: Contribution to journalArticle

Bleyer, Archie ; Choi, Mehee ; Fuller, C. David ; Thomas, Charles ; Wang, Samuel. / Relative Lack of Conditional Survival Improvement in Young Adults With Cancer. In: Seminars in Oncology. 2009 ; Vol. 36, No. 5. pp. 460-467.
@article{534f582f6a9349b2b9b45b27746049b9,
title = "Relative Lack of Conditional Survival Improvement in Young Adults With Cancer",
abstract = "Cancer prognosis is usually reported in terms of survival from time of diagnosis. For patients surviving a period of time after diagnosis, conditional survival (CS) accounts for changing risk over time. This report provides information on how CS in cancer patients changes as a function of age at diagnosis. Using data from the US Surveillance, Epidemiology and End Results database, we examined survival for patients diagnosed between 1973 and 2002. The average annual percent change (AAPC) in CS during the first 5 years after diagnosis was evaluated for the 14 most common cancers occurring in young adults, defined as 15- to 39-year-olds, and how they compared with cancers that are more common in older and younger patients. For all cancers, young adult patients had less CS improvement over time than younger or older patients, and this difference was most pronounced in those aged 20 to 29 years (45{\%} below the mean). Eleven of the 14 most common cancers in 15- to 39-year-olds either had a lower CS improvement after diagnosis than either younger or older patients, or than just the older patients. Young adults with leukemia had the greatest improvement in CS over time. In conclusion, young adults with cancer have not enjoyed the same improvement in CS over time compared with other age groups. Explanations for this deficit include the biologic nature of the type of cancers in young adults and less effective therapies for patients in the age group. Regardless of the reasons, the deficit is yet another challenge faced by young adult patients that merits further study.",
author = "Archie Bleyer and Mehee Choi and Fuller, {C. David} and Charles Thomas and Samuel Wang",
year = "2009",
month = "10",
doi = "10.1053/j.seminoncol.2009.07.004",
language = "English (US)",
volume = "36",
pages = "460--467",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Relative Lack of Conditional Survival Improvement in Young Adults With Cancer

AU - Bleyer, Archie

AU - Choi, Mehee

AU - Fuller, C. David

AU - Thomas, Charles

AU - Wang, Samuel

PY - 2009/10

Y1 - 2009/10

N2 - Cancer prognosis is usually reported in terms of survival from time of diagnosis. For patients surviving a period of time after diagnosis, conditional survival (CS) accounts for changing risk over time. This report provides information on how CS in cancer patients changes as a function of age at diagnosis. Using data from the US Surveillance, Epidemiology and End Results database, we examined survival for patients diagnosed between 1973 and 2002. The average annual percent change (AAPC) in CS during the first 5 years after diagnosis was evaluated for the 14 most common cancers occurring in young adults, defined as 15- to 39-year-olds, and how they compared with cancers that are more common in older and younger patients. For all cancers, young adult patients had less CS improvement over time than younger or older patients, and this difference was most pronounced in those aged 20 to 29 years (45% below the mean). Eleven of the 14 most common cancers in 15- to 39-year-olds either had a lower CS improvement after diagnosis than either younger or older patients, or than just the older patients. Young adults with leukemia had the greatest improvement in CS over time. In conclusion, young adults with cancer have not enjoyed the same improvement in CS over time compared with other age groups. Explanations for this deficit include the biologic nature of the type of cancers in young adults and less effective therapies for patients in the age group. Regardless of the reasons, the deficit is yet another challenge faced by young adult patients that merits further study.

AB - Cancer prognosis is usually reported in terms of survival from time of diagnosis. For patients surviving a period of time after diagnosis, conditional survival (CS) accounts for changing risk over time. This report provides information on how CS in cancer patients changes as a function of age at diagnosis. Using data from the US Surveillance, Epidemiology and End Results database, we examined survival for patients diagnosed between 1973 and 2002. The average annual percent change (AAPC) in CS during the first 5 years after diagnosis was evaluated for the 14 most common cancers occurring in young adults, defined as 15- to 39-year-olds, and how they compared with cancers that are more common in older and younger patients. For all cancers, young adult patients had less CS improvement over time than younger or older patients, and this difference was most pronounced in those aged 20 to 29 years (45% below the mean). Eleven of the 14 most common cancers in 15- to 39-year-olds either had a lower CS improvement after diagnosis than either younger or older patients, or than just the older patients. Young adults with leukemia had the greatest improvement in CS over time. In conclusion, young adults with cancer have not enjoyed the same improvement in CS over time compared with other age groups. Explanations for this deficit include the biologic nature of the type of cancers in young adults and less effective therapies for patients in the age group. Regardless of the reasons, the deficit is yet another challenge faced by young adult patients that merits further study.

UR - http://www.scopus.com/inward/record.url?scp=70349768052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349768052&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2009.07.004

DO - 10.1053/j.seminoncol.2009.07.004

M3 - Article

C2 - 19835741

AN - SCOPUS:70349768052

VL - 36

SP - 460

EP - 467

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5

ER -